Related Image: Scientists develop new measure of 'socioclimactic' risk |
(Date:11/4/2009)...an has received more than $10 million in research ...ederal stimulus program, bringing thetotal amount ...$23 million. Thirty-three projects achieved stimu...o weather. , "The university has thoughtfully un... scholarly excellence to federal agency priorities...
(Date:11/4/2009)...re/ -- What,s the cost of saving a teenage life? W...ing from prescription medication abuse, there,s no... may be unaware that the lock-boxes they,ve instal...g timebomb of prescription drugs. That,s why MEDNE...l supplies, has formed an exclusive partnership wi...
(Date:11/4/2009)...wswire/ -- GenVault Corporation (Carlsbad, CA) tod...joined its Board of Directors. Dr. Brody, the Irw..., is an acclaimed physician-scientist and universi...r. Brody served as president of The Johns Hopkins ...y of Engineering and the Institute of Medicine, an...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Hormone therapy may confer more aggressive properties to prostate tumors 48453 1Drugs against winter vomiting disease one step closer 48451 1Drugs against winter vomiting disease one step closer 48451 2New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 1New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 2(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...RDOVA, Calif., Nov. 5 Th...lier of innovative products for processing and sto...the first quarter of fiscal 2010. ,, For the qu...ed revenues of $5.2 million, a 15 percent increase...r a year ago. The Company said the key contributor...
(Date:11/5/2009)..., Calif., Nov. 5 Cepheid...ves will be speaking at the following investor con... webcast. , , Credit Suisse Health...sday, 12 November, 2009 at 10 a.m. Mountain Time,... London, England, Tuesday, 1 Decem...
(Date:11/5/2009)...exas, Nov. 5 SpineSmith Partners h... to co-develop a unique scaffold that mimics the s...aluation of several commercial products by SpineSm...pany believes the GenOsteo scaffold represents a s...a unique and ideal environment for the delivery of...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2...SAN DIEGO, March 2 BioMed Realty Trust, Inc. (NYS...cutive management will present at the Citi 2009 Gl... approximately 9:05 a.m. Eastern Standard Time on ...ll be open to all investors by calling 719.785.559...ioMed Realty Trust , BioMed Realty Trust, Inc. is...
..., Innovative B.C. Technology Promises to Revolu...ER, March 2 /PRNewswire-FirstCall/ - EnWave Corpor...ay announced that it has completed the first sale ...uipment to CAL-SAN Enterprises, Ltd. of Richmond, ...producers. With this sale, EnWave has proven that ...
... EXTON, Pa., March 2 Morphotek(R), Inc., a sub...ay announced that it has commenced a,multi-centere...ody in,mesothelioma. The study will evaluate MORAb...isplatinum, as a first-line treatment for patients... the study is to assess the efficacy of MORAb-009,...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Starter Accessory Package I from Bethyl Laboratories
Rabbit Anti-Human Purinergic Receptor P2Y12 Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human CLAN Polyclonal Antibody, Unconjugated from IMGENEX
Acridinium Quench Solution from Cayman Chemical
Biology Products: